Eli Lilly and Company (NEO:ZLLY)

Market Cap	1.58T +81.5%
Revenue (ttm)	113.13B +49.6%
Net Income	37.93B +93.6%
EPS	42.30 +94.8%
Shares Out	n/a
PE Ratio	41.58
Forward PE	32.41
Dividend	0.05 (0.40%)
Ex-Dividend Date	May 15, 2026

Volume	n/a
Open	12.82
Previous Close	12.82
Day's Range	12.82 - 12.82
52-Week Range	9.09 - 13.11
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 50,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ZLLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 19, 2026

Data Sources Report a data error